You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

September 9, 2026

Indonesia’s Updated Regulation on Food Packaging

On June 30, 2026, Indonesia’s National Agency of Drug and Food Control (BPOM) issued BPOM Regulation No. 11 of 2026 on Food Packaging, which expands the list of approved food-contact substances and recognizes a broader range of permissible functions for those substances. The new regulation, which revokes BPOM Regulation No. 20 of 2019, reflects developments in packaging technology and materials science.

Although the new regulation provides more advantages to business actors by adding more food contact substances to the approved list for use in food packaging, there are more stringent rules and restrictions for testing. One of the most significant changes is a comprehensive migration-testing framework that sets out requirements for packaging materials, testing conditions, food simulants, and specific migration limits.

Overall and Specific Migration

Under BPOM Regulation No. 20 of 2019, migration requirements were primarily set out within the lists of approved food-contact substances and packaging materials. BPOM Regulation No. 11 of 2026 instead expressly requires packaging materials that come into direct contact with food to meet both overall and specific migration limits. These are defined as follows:

  • Overall migration: The total quantity of all substances that migrate from the packaging, regardless of whether the substances are hazardous or nonhazardous to health.
  • Specific migration: The quantity of a particular identified substance known to be hazardous to health that migrates from the packaging.

Stricter Limits on Heavy Metals

The overall migration limit for plastic packaging remains unchanged under both regulations at 60 mg/kg or 10 mg/dm². However, the new regulation introduces significant changes to the regulation of heavy metals. Under the 2019 regulation, four heavy metals—lead, cadmium, chromium VI, and mercury—were subject to a single combined limit of 1 mg/kg. The 2026 regulation, however, requires each heavy metal to meet its own individual specific migration limit, adds arsenic as a newly regulated substance, and broadens the scope of chromium testing from chromium VI (Cr(VI)) to total chromium (Cr). The specific migration limits under the 2026 Regulation are set out below:

  • Arsenic (As): Not detected (LOD 0.01 mg/kg)
  • Cadmium (Cd): Not detected (LOD 0.002 mg/kg)
  • Total Chromium (Cr): Not detected (LOD 0.01 mg/kg)
  • Lead (Pb): 0.05 mg/kg
  • Mercury (Hg): Not detected (LOD 0.01 mg/kg)

Updated Rules on Food Simulants

A food simulant is a medium used to mimic the characteristics of a particular food to simulate the migration of components from the food packaging into the food. The 2026 regulation identifies five types of food simulants for use in overall migration testing, as follows:

  • Simulant A: Ethanol 10% (v/v)
  • Simulant B: Acetic acid 3% (w/v)
  • Simulant C: Ethanol 20% (v/v)
  • Simulant D1: Ethanol 50% (v/v)
  • Simulant D2: Vegetable oil containing less than 1% unsaponifiable matter; if food simulant D2 cannot be used, 95% alcohol or isooctane may be used as an alternative food simulant
  • Simulant E: Poly (2,6-diphenyl-p-phenylene oxide), particle size 60–80 mesh, pore size 200 nm

Under the 2019 regulation, simulant D2 was defined as vegetable oil, with no specific compositional requirements. The 2026 regulation narrows this definition and provides an alternative for situations where simulant D2 cannot be used.

New Requirements for Food Product Composition

The 2026 regulation introduces new disclosure requirements for the composition of food products that may come into contact with their packaging material. The name, percentage, and function of each component must be declared, and the sum of all declared percentages must equal 100%.

New Testing Requirements for Reusable Plastic Packaging

The 2026 regulation introduces additional requirements for reusable food packaging. Reusable plastic packaging must meet both the overall and specific migration limits through the testing protocol prescribed in Annex V.

For overall migration, compliance may be demonstrated in a single test. If the first result meets the applicable limit, no further testing is required. If it does not, up to two additional tests are permitted, provided that the results show a decreasing trend, with the second result lower than the first, and the third lower than the second.

Specific migration, by contrast, requires three tests in order to simulate the repeated contact that occurs over the packaging’s service life. Each result must meet the applicable specific migration limit, and the levels must not increase across the cycles; the second result may not exceed the first, and the third may not exceed the second. Compliance depends on these results, as well as on the stability of the packaging material throughout the three testing cycles. A material is considered unstable if detectable migration increases from the first test to the third, even when the migration values remain below the applicable regulatory limit.

Because contact under single-use conditions represents the worst-case scenario for migration, test data generated under those conditions is generally understood to support compliance for repeated-use applications as well.

Transition Period

BPOM Regulation No. 11 of 2026 provides a 12-month transition period from its promulgation date to allow food packaging products already circulating in the market to comply with the new requirements. Food packaging that was already in circulation before the regulation entered into force must be brought into compliance with the new regulation by June 30, 2027.

Business Impact

BPOM Regulation No. 11 of 2026 updates Indonesia’s food packing rules to better respond to developments in food packaging technology and materials science. Food packaging manufacturers, importers, and brand owners in Indonesia should review existing compliance practices and test reports to confirm that packaging intended for direct food contact meets the new overall and specific migration requirements.

RELATED INSIGHTS​ 

June 17, 2026
Thailand’s new labeling requirements for medical devices, which include for the first time a unique device identification (UDI) requirement for software as a medical device (SaMD), take effect on June 20, 2026. The Notification of the Ministry of Public Health regarding Criteria, Methods, and Conditions on Labeling and Instructions for Use for Medical Devices 2025, which replaces a similar notification from 2020, was published in the Government Gazette on December 22, 2025. To ensure clarity, modernity, and patient safety, the regulation requires domestic manufacturers and importers to provide labels and instructions for use (IFU) that are clearly legible, complete, and free of false or misleading claims. It also permits IFU to be provided in electronic format, such as via QR codes, websites, or other digital channels—directly relevant to SaMD, where physical labels are impractical and electronic presentation is the natural medium. The notification distinguishes two categories for labeling language. Home-use medical devices (for lay users outside healthcare facilities) must have labels and IFU in Thai. Professional-use medical devices may display labels and documentation in either Thai or English. This distinction is significant for SaMD developers: software intended for clinical professionals may use English-language interfaces and IFU, while consumer-facing health applications must provide Thai-language content. Labeling and UDI Requirements Labels and IFU must include, at a minimum: Product name and intended purpose Quantity or volume Name and address of domestic manufacturer or importer Thai FDA approval number Lot, version, or serial number Manufacturing date and expiry date For SaMD, the version number requirement is particularly relevant. The regulation also mandates display of a UDI code for SaMD in risk category 2 (moderate-risk), category 3 (moderate- to high-risk), and category 4 (high-risk), according to Thailand’s medical device risk classification system (which complies with the ASEAN Medical Device Directive and the EU
June 5, 2026
On May 25, 2026, Vietnam’s Ministry of Health issued Circular No. 16/2026/TT-BYT governing free-of-charge medicine support programs for medical establishments (Circular 16). Circular 16 will take effect on July 10, 2026, replacing Circular No. 31/2018/TT-BYT, which currently regulates the same subject matter. Circular 16 introduces several significant changes compared to the existing legal framework. Removal of Prior Approval Requirement Under the current regulations, free-of-charge medicine support programs are divided into two categories: (1) entirely free-of-charge provision of medicines for all types of drugs and (2) partially free-of-charge provision applicable only to brand-name drugs under patent protection or drugs whose generic products with identical active ingredients and dosage forms are available in Vietnam. Under the current regulations, partially free-of-charge programs are subject to mandatory registration with the competent authority, while entirely free-of-charge programs could be implemented without prior approval. A key reform under Circular 16 is that it stipulates only entirely free-of-charge medicine support programs applicable to all types of medicines, thereby eliminating the partially free-of-charge category. In addition, free-of-charge medicine support programs may be carried out solely based on a written agreement between the pharmaceutical company and the medical establishment, without any requirement for prior approval from competent authorities prior to implementation. Written Agreement Requirements Circular 16 requires the pharmaceutical company and medical establishment to enter into a written agreement in accordance with a prescribed template. This agreement must include the following compulsory information: Information on the supported medicines Form of support (entirely free-of-charge provision to patients) Quantity of medicines provided Target patient groups and applicable indications Duration of the program Rights and obligations of each party Transitional provisions on the protection of patients’ rights upon completion of the program The agreement may contain other contents as agreed by the parties, provided that these do not contradict applicable laws.
June 4, 2026
Indonesia’s Minister of Health has issued Decree No. HK.01.07/MENKES/301/2026 on the Affixation of Nutritional Labels and Health Information to Ready-to-Eat Processed Food Products. The decree came into force on April 14, 2026, and was issued to implement the Health Law and Minister of Health Regulation No. 3 of 2026 on Disease Control. The decree requires the inclusion of Nutri-Level labeling on the front-of-pack nutrition labeling (FOPNL) to indicate the product’s nutritional level based on the content of sugar, salt, and fat (“gula, garam dan lemak (GGL)”). Changes from 2024 Draft Regulation The Nutri-Level labeling was previously proposed in 2024 by the Indonesian FDA (BPOM) through a draft regulation concerning nutrition information. While the categories of Nutri-Level labeling remain the same in the issued decree, the content requirements of sugar, salt and fat in the decree are different from the earlier proposal introduced in the 2024 draft BPOM regulation. In addition, the decree has further specified that the content of fat in the Nutri-Level labeling is the content of saturated fat, not total fat as previously proposed in the 2024 draft. The decree requires Nutri-Level labeling to be implemented in beverage products, which is the same as previously proposed in the 2024 draft BPOM regulation. Other food products may gradually become subject to mandatory Nutri-Level labeling under future implementing regulations. Nutri-Level Labeling Food levels as shown by the Nutri-Level labeling are classified into four color-coded categories from A to D: Level A (lowest amount) in dark green Level B in light green Level C in yellow Level D (highest amount) in red The Nutri-Level labeling is represented by the following image. The requirements for each level for sugar, salt, and fat content, based on amounts per 100 milliliters of product in beverage form, are as follows. Nutri-Level information must be
May 29, 2026
Indonesia’s Food and Drug Authority (BPOM) has issued Regulation No. 7 of 2026 on Drug Promotion and Advertising, establishing an updated framework for promotional activities involving medicinal products in Indonesia. The regulation took effect on April 16, 2026, and supersedes BPOM Regulation No. 2 of 2021 on Drug Advertising Supervision. The new regulation maintains general principles for advertising content, including requirements that advertisements be objective, complete, and not misleading, as further detailed in its annex. It also confirms that advertisements for nonprescription drugs directed to the public must obtain prior approval from BPOM before publication and must be in Bahasa Indonesia. The regulation provides a more comprehensive framework governing how drug promotion is conducted, introducing several notable additions and changes, as described below. Procedure and Requirements for Drug Advertisement Approval To apply for a drug advertisement approval, applicants must create an online account through the dedicated portal SIAPIK. Advertisement approval is available only for registered drugs; unregistered drugs are not eligible for advertisement approval with BPOM. The application must include the advertisement design, along with a translation if the design contains any wording in a foreign language. The submission format varies by media type, requiring, for example, copies in the form of print advertisements for visual media, scripts for audio media, and storyboards for audiovisual media. For online media—including social media—submissions should include any captions, descriptions, and hashtags that form an integral part of the advertising material. The approval timeline takes approximately 3–4 months, as BPOM will generally request additional information or revisions during the verification and evaluation process. Applicants have 20 days to submit any such requested documents. BPOM may also conduct a reevaluation of advertisements that have already received approval, based on monitoring results or new information regarding the safety and quality of the advertised drug. This